EU/3/19/2170

Table of contents

About

On 28 June 2019, orphan designation EU/3/19/2170 was granted by the European Commission to Vifor France S.A., France, for 2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride (also known as VIT-2763) for the treatment of beta-thalassaemia intermedia and major.

Key facts

Active substance
2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridine-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride
Disease / condition
Treatment of beta-thalassaemia intermedia and major
Date of first decision
28/06/2019
Outcome
Positive
EU designation number
EU/3/19/2170

Sponsor's contact details

Vifor France S.A.
Tour Franklin La Defense 8
100-101 Terrasse Boieldieu
Puteaux
92042 Paris La Defense Cedex
France 
Tel. +33 1410 65890; +41 5885 18000 (Switzerland)
E-mail: info@viforpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating